Here, we show that through shRNA knockdown studies, TGFβ2 directly mediates the survival of the adaptive EGFR-TKI drug-escaping tumor cells, and that it also directly regulates the mitochondrial BCL-2/BCL-xL expression downstream, but not BIM. The gene discussed is BCL2; the disease is neoplasm.